Inflammatory responses after intracoronary injection of autologous mononuclear bone marrow cells in patients with acute myocardial infarction - 09/08/11
, Ingebjørg Seljeflot, PhD a, b, Ketil Lunde, MD c, Pål Aukrust, MD, PhD d, e, Arne Yndestad, PhD d, Haakon Kiil Grøgaard, MD a, Svend Aakhus, MD, PhD c, Kolbjørn Forfang, MD, PhD c, Harald Arnesen, MD, PhD aRésumé |
Background |
Inflammatory responses after intracoronary injection of autologous mononuclear bone marrow cells (mBMC) are not clarified. The aim of this study was to investigate the influence of intracoronary injection of mBMC on inflammatory mediators in patients with acute myocardial infarction (AMI).
Methods |
Patients with AMI in the ASTAMI trial (N = 100) treated with percutaneous coronary intervention were randomized to intracoronary injections of mBMC or control. Fasting blood samples were drawn the day before stem cell transplantation (baseline 4-5 days after AMI) and 1 day, 3 days, 2 to 3 weeks, and 3 months after transplantation for determination of circulating levels of selected inflammatory markers and mRNA levels in whole blood samples.
Results |
From baseline to day 1, the levels of interleukin 6 and the expression of tumor necrosis factor α mRNA increased significantly in the mBMC group compared to the control group (P < .05 for both).
The decrease in interleukin 6 levels from baseline to 2 to 3 weeks in the mBMC group was less pronounced than in the controls (P < .05), as was also the decrease in C-reactive protein levels from baseline to day 1 and day 3 in the mBMC group (P < .05). However, from baseline to 3 months the levels of tumor necrosis factor α and monocyte chemoattractant protein 1 increased less in the mBMC group (P < .05 for both).
Conclusion |
Intracoronary injection of mBMC in patients with AMI induces a marked short-term inflammatory response, but a slightly reduced inflammation after 3 months which may have implications for the timing of stem cell transplantation in AMI.
Le texte complet de cet article est disponible en PDF.Plan
| Dr S Solheim and Dr K Lunde are supported by research fellowships from the Norwegian Council on Cardiovascular Diseases, Oslo, Norway. Additional financial support was given by Ullevål University Hospital Scientific Advisory Council, Oslo, Norway. |
Vol 155 - N° 1
P. null - janvier 2008 Retour au numéro
Article précédent
- Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
- David A. Morrow, Yunmei Wang, Kevin Croce, Masashi Sakuma, Marc S. Sabatine, Huiyun Gao, Aruna D. Pradhan, Aileen M. Healy, Jacki Buros, Carolyn H. McCabe, Peter Libby, Christopher P. Cannon, Eugene Braunwald, Daniel I. Simon
- Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: A potential approach to identify atherosclerotic disease progression
- Paul A. Gurbel, Rolf P. Kreutz, Kevin P. Bliden, Joseph DiChiara, Udaya S. Tantry
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?